8-K current report · filed Nov 5, 2026

Aquestive Therapeutics, Inc. (AQST) 8-K Current Report: November 5, 2026

Item 7.01Item EX-99.1AQST overview

Short answer

Aquestive Therapeutics, Inc. (AQST) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Investor presentation disclosed under Regulation FD for institutional investor and analyst meetings.

Aquestive Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Investor presentation disclosed under Regulation FD for institutional investor and analyst meetings
  • Presentation likely contains current strategic, pipeline, or financial updates, with details in Exhibit 99.1
  • Investors should monitor subsequent filings for amended or updated information

Item EX-99.1 · Exhibit EX-99.1

  • Anaphylm NDA resubmission accepted, with FDA PDUFA goal date March 16, 2027
  • Regulatory catalyst remains binary: FDA may approve, request additional information, or issue another rejection
  • Cash $90.3M as of September 30, 2026, plus potential $75M strategic funding and $20M debt access, both conditionally available
  • Pipeline opportunity includes potential peak annual sales above $1B for Anaphylm, above $500M for AQST-108, and above $100M Libervant sales
  • Canada filing targeted by year-end 2026 and European Union filing in Q1 2027, expanding potential regulatory catalysts beyond the U.S.

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Aquestive Therapeutics, Inc. 8-K filings

Get the next AQST 8-K as it lands

Follow AQST for push alerts, or ask the research agent what this filing means.